The prevalence of sarcopenia and cachexia in older patients with localized colorectal cancer
- PMID: 36424269
- DOI: 10.1016/j.jgo.2022.11.001
The prevalence of sarcopenia and cachexia in older patients with localized colorectal cancer
Abstract
Introduction: The incidence of colorectal cancer (CRC) increases with age. In combination with an ageing population, the number of older patients undergoing surgical treatment for CRC is therefore expected to increase. Sarcopenia and cachexia are potentially modifiable risk factors of a negative surgical outcome. Sarcopenia can be categorized into primary (age-related) and secondary where diseases, such as malignancy, are influential factors. We aimed to investigate the prevalence of preoperative sarcopenia and cachexia in older (≥65 years) vulnerable patients with localized CRC.
Materials and methods: Patients included in the randomized study "Geriatric assessment and intervention in older vulnerable patients undergoing resection for colorectal cancer," were screened for sarcopenia and cachexia prior to surgery. All patients in the present cohort were considered vulnerable with Geriatric 8 ≤ 14 points. Sarcopenia was defined according to European Guidelines (EWGSOP2), based on low muscle strength-low handgrip-strength and/or slow 5xChair-Stand-Test-and low appendicular lean mass assessed by dual-energy X-ray absorptiometry. Cachexia was defined as self-reported unintended weight loss >5% within three months or 2-5% with body mass index <20 kg/m2.
Results: Sixty-four patients (mean age 79.6 years ±6.4 years, 36 women) were assessed. Of these, 28% (n = 18, 11 women) had low muscle strength and 13% (n = 8, 4 women) fulfilled the criteria for sarcopenia, however, 33% (n = 21, 13 women) had low muscle mass. There was no correlation between low muscle strength and low muscle mass (r = 0.16, P = 0.22). The prevalence of cachexia was 36% (n = 23, 16 women). Low muscle mass was associated with cachexia (φ = 0.38, P = 0.005), but there was no association between sarcopenia and cachexia (φ = 0.01, P = 1.0).
Discussion: Despite the included patients who fulfilled the criteria for vulnerability according to G8, relatively few (28%) had low muscle strength. Moreover, there was poor overlap between the prevalence of sarcopenia according to the EWGSOP2 guidelines (13%) and prevalence of low muscle mass (33%) in older patients with CRC. Of note also, there was no association between sarcopenia and cachexia, but an association between cachexia and low muscle mass, which highlights the importance of assessing muscle mass in patients with cancer.
Trial registration: The GEPOC trial has been prospectively registered at http://clinicaltrials.gov (NCT03719573).
Keywords: Cachexia; Colorectal cancer; Dual-energy X-ray absorptiometry; Geriatric- 8 screening tool; Handgrip-strength; Older patients; Sarcopenia; Vulnerability.
Copyright © 2022. Published by Elsevier Ltd.
Similar articles
-
Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial).BMC Geriatr. 2021 Jan 30;21(1):88. doi: 10.1186/s12877-021-02045-9. BMC Geriatr. 2021. PMID: 33516195 Free PMC article.
-
The choice of diagnostic modality influences the proportion of low muscle strength, low muscle mass, and sarcopenia in colorectal cancer patients.Clin Nutr ESPEN. 2024 Apr;60:17-23. doi: 10.1016/j.clnesp.2024.01.001. Epub 2024 Jan 11. Clin Nutr ESPEN. 2024. PMID: 38479906
-
Sarcopenia definitions and their association with fracture risk in older Swedish women.J Bone Miner Res. 2024 May 2;39(4):453-461. doi: 10.1093/jbmr/zjae026. J Bone Miner Res. 2024. PMID: 38477811 Free PMC article.
-
Risk of secondary sarcopenia in Europeans with fibromyalgia according to the EWGSOP2 guidelines: systematic review and meta-analysis.Eur J Phys Rehabil Med. 2024 Aug;60(4):703-715. doi: 10.23736/S1973-9087.24.08348-5. Epub 2024 Jun 11. Eur J Phys Rehabil Med. 2024. PMID: 38860694 Free PMC article.
-
Treatment opinion of rehabilitation in sarcopenia and cachexia for oncological patients.Klin Onkol. 2020 Winter;33(6):421-425. Klin Onkol. 2020. PMID: 33685190 Review. English.
Cited by
-
Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system.Cancer Rep (Hoboken). 2024 May;7(5):e2100. doi: 10.1002/cnr2.2100. Cancer Rep (Hoboken). 2024. PMID: 38775250 Free PMC article.
-
The effect of resistance training on patients with secondary sarcopenia: a systematic review and meta-analysis.Sci Rep. 2024 Nov 20;14(1):28784. doi: 10.1038/s41598-024-79958-z. Sci Rep. 2024. PMID: 39567607 Free PMC article.
-
Clinical Relevance of Physical Function Outcomes in Cancer Cachexia.Cancers (Basel). 2024 Apr 1;16(7):1395. doi: 10.3390/cancers16071395. Cancers (Basel). 2024. PMID: 38611073 Free PMC article. Review.
-
Sarcopenia and sarcopenic obesity among older adults in the nordic countries: a scoping review.BMC Geriatr. 2024 May 13;24(1):421. doi: 10.1186/s12877-024-04970-x. BMC Geriatr. 2024. PMID: 38741067 Free PMC article.
-
Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.Int J Mol Sci. 2025 Apr 22;26(9):3952. doi: 10.3390/ijms26093952. Int J Mol Sci. 2025. PMID: 40362192 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical